AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: AnCan’r considering AMG509 STEAP T-Cell engager; does IDC-P make you high risk?
Topics Discussed
Newbie needs GU MO and doublet; ADT and heart issues; BRCA2 germline Gent progresses after P; no evidence for doublet; long-timer needs to switch treatment; moving from Pluvicto to xaluritamig/ AMG509/ STEAP trial; supplemental E2 discussed by peer – insurance issues, gui9dance on E2 blood levels; IDC-P man on RT asks how much HT; with BCR, doubling time may be more significant guide to BCR than actual PSA level
Chat
Jim Marshall, Vet Support Grp. Moderator sent: 6:33 PM
Joining from the air. No mic available. I just blogged the Estradiol conversation.
AnCan – Rick sent: 7:36 PM
Kishan would say 6 months per his recent meta study
Show Tran the Kishan paper
Jeff Marchi – San Francisco sent: 7:37 PM
has he had genetic testing? it can frequently be associated with genetic issues
AnCan – Rick sent: 7:37 PM
12 months if you’re more aggressive.
Is Spratt the final author
Steve Schuler (Seattle) sent: 7:40 PM
I just wrapped it up a month ago. Now I’m on nothing, no ADT either. I was on Lupron for 2 years, abiraterone also for 2 years, but started a year after the Lupron started (there’s a story there, but later), and then on Estradiol for most of the time I was on abiraterone. But now on nothing. For most of the E2, it was .05mg (50 microgram) patches 2 per week. So a box of 8 lasts you 4 weeks. With GoodRX, those were $13/box
A word about the dose level of the patches: that’s the estimated dose delivery of a patch per day. The amount of E2 in the patch itself is higher, something like 600 microgram is what I remember, but then it releases slowly at an ESTIMATED rate of 50. But that release rate is highly dependent on the amount of fat under the skin, etc. So your milage will vary
Mark N sent: 7:44 PM
Thanks for the feed back!
dan-s alexandria sent: 7:48 PM
thanks Jimmy
Pierre D., Olean, NY sent: 7:52 PM
Thank you all for your input.
Jeffrey G sent: 7:53 PM
We were in the 90s today. Ugh, warmest AZ winter i’ve ever been in. Still, gotta be grateful for warm weather and for a psa of 0.02…Adios
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Cribriform complicates treatment decision; and we discuss NCI trial
Topics Discussed
Over-70 KP ‘Couple’ insisted on PSA against protocol and found 4+4 cancer – cribriform complicates Tx decision; recently Dx denovo Mx ‘Couple’ seeking their way; recurrence after 7 years may set up well for NCI trial; high Decipher and cribriform may point to doublet; NCI Playing the Long Game discussed – Dr. Paul rightly finds it antithetical; Natera trial result reports zero level ctDNA; leg pain after starting doublet HT; push the IHT 3 more months with diligent AS; estradiol vets defer conversation to next week; side effects of radiation treatment
Is Gallium – 68 the more sensitive recommended radioactive tracer to use for a PSMA-PET Scan? Just wondering if seeking the best tracer produces better results.
DISCLAIMER: AnCan does not endorse Superpower or any of its products. All patients should discuss with their healthcare provider before using any of their products or any of the tests or advice in the article.
In another of the seemingly endless organizations offering premium health services, Superpower, founded in 2023, provides a fairly straightforward overview of the myriad tests and biomarkers available to Prostate Cancer patients (A Clear Guide to PCa Biomarkers). Seasoned AnCaners may find little new in here, especially those that attend or review many of the recent seminars/webcasts, but newcomers or those needing a refresher may find it helpful for further research or equipping you to be your own best advocate. The article hits many of the main tests with which we are all familiar, as well as some of the urine biomarkers (PCA3, Select MDx, ExoDX), without specifically endorsing any of them. It does touch on MRIs, but only multi-parametric, not bi-parametric MRIs, nor does it get into the trans-rectal versus trans-perineal debate. Be forewarned, there is information with which not everyone will agree (shocking, I know), but it is still a useful, albeit somewhat rudimentary tool.
Interpreting Prostate Needle Biopsies in Today’s World
Interpreting Prostate Needle Biopsies in Today’s World
Dr. Jonathan Epstein, MD, Advanced Uropathology
Reliable biopsies are critical to selecting the right treatment at all stages of prostate cancer – we’re talking needle tissue, not blood, btw. Get it wrong and you may get too much or too little treatment.
Reading pathology is part art and part science! AnCan Advisory Board Member, Dr. Jonathan Epstein is globally acknowledged to have the best eye in the genitourinary pathology world. AnCan frequently refers men to him for a 2nd opinion. His presentation will include:
Getting the most out of a 2nd Opinion
The relevance of cribriform, intraductal, ductal, & small cells
Hi-Risk/Recurrent/Advanced PCa Video Chat, May 5, 2025
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix, Blue Earth Diagnostic and Foundation Medicine.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime!
Editor’s Pick: How to follow PARP-I for BRCA1 Gent (rd)
Topics Discussed
Setting up for recurrence treatment in Alberta, Canada; PSMA rules out Mx, but what about other pelvic issues – bone Bx to follow; debulk IMRT done – SBRT boost to follow; 2 Pluvicto sessions reveal good progress; 90 days max for vacay meds on Medicare; is darolutamide monotherapy enough?; will new test to replace PSA work for recurrence?; how long to PSA nadir on HT?; Tricare alone not enough – join Vets to learn how to dual enroll; Payer denies Orgovyx – what to do; Marine Chaplain can’t find his voice – so uses Chat!
